Deals In Depth: September 2010
Executive Summary
With the largest up-front ever for a Phase II candidate, Abbott's license to Reata's CKD compound bardoloxone topped the September alliance list. J&J expanded into vaccines through the Crucell buy, and Genzyme divested its esoteric testing division Genzyme Genetics to LabCorp for $925 million. Biopharma FOPOs and early-stage VC rounds were the most lucrative financing vehicles in September, with each type bringing in around $180 million of the $691 million total. The majority of device fundraising came from MicroPort Scientific's IPO.